Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0792
    -0.0037 (-0.35%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2625
    -0.0013 (-0.10%)
     
  • USD/JPY

    151.4010
    +0.1550 (+0.10%)
     
  • Bitcoin USD

    70,820.32
    +1,448.38 (+2.09%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Consilium Global Research Issues Quarterly Update on Zynex, Inc (OTCQB: ZYXI)

ST. PETERSBURG, FL / ACCESSWIRE / May 18, 2018 / Consilium Global Research (CGR) an Investor Recognition Company that connects Companies with Investors, today announced that it has issued an Update Report on Zynex Inc. (ZYXI).

The Research Update Report is available on Stock Market Manager (www.smm.global): Click Here

Zynex is the leading provider of Electrotherapy Medical Devices used for pain management and rehabilitation. The company is also pioneering development of an Innovative Blood Volume Monitor.

Catalysts/Keys:

1. ZYXI reported 1Q18 EPS of $0.06 on revenue of $6.9 million, in-line with our forecast of $0.06 on revenue of $7.0 million. This compares to 1Q17 revenue of $3.4 million on EPS of $0.01. The growth on the top-line this quarter is up 100% over 1Q17 versus -1% growth Y/Y in 1Q17 over 1Q16. We believe this is exceptional as growth in this quarter is typically seasonally the lowest.

2. Management took this opportunity to provide guidance for 2Q18E. Management expects revenue in the range of $7.5- $8.0 million, EBITDA in the range of $2.5 - $3.0 million and EPS of $0.08.

3. As a result of this quarter's performance, management's guidance and our follow-up conversations with management; we are making modest tweaks to our model. For 2018E we now forecast revenue of $31.9 million down from $34.2 million previously. As mentioned, device order growth was impressive during the quarter, but we are playing it conservative as to when it will benefit the quarters throughout the year. For 2018E we now forecast EBITDA of $11.7 million, up from $7.3 million previously. For 2018E our EPS forecast remains unchanged at $0.31. For 2019E we now forecast revenue of $44.6 million ($47.9 million previously), EBITDA of $15.6 million ($9.5 million previously) and EPS of $0.41 (unchanged).

Conclusion Our Investment Thesis is intact and we are glad to see that the ongoing paradigm shift at ZYXI is proving beneficial to investors. As a result of our new forecasts we are leaving our fair value estimate of $7 unchanged, which assumes ZYXI can achieve an EV/EBITDA of 15.8x (11.6x previously), 17.1x P/E (17.2x previously) and EV/Sales of 5.5x (2.4x previously). Given the increased predictably/stability of the financials, we believe the modest change to the target multiples is appropriate.

Contact Information:

Consilium Global Research
360 Central Ave, Suite 800
St. Petersburg, FL 33701
www.ConsiliumGlobalResearch.com
info@ConsiliumGlobalResearch.com

Zynex Medical, Inc.
9555 Maroon Circle Englewood,
CO, 80112
(800) 495-6670
www.zynexmed.com
info@zynex.com

About Stock Market Manager

Stock Market Manager operates a proprietary system for distribution of press releases, research and corporate news to its database of investors and financial professionals of over 300,000 as well as financial terminals, print, broadcast and trade media, wire services, news agencies, and other portals, websites, and social media. The news distribution system allows companies to distribute news and information to their shareholders in real time and incorporates access to quotes, filings, and financial information through its quote media service. SMM.global specializes in providing independent research on small and micro-cap companies.

Website: www.smm.global

Carl Dilley
President
727-823-3987
cdilley@smm.global

SOURCE: Stock Market Manager

Advertisement